Vertex Pharmaceuticals (VRTX) Cash from Investing Activities (2009 - 2026)

Vertex Pharmaceuticals' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$431.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 674.01% year-over-year to -$431.9 million; the TTM figure through Mar 2026 stood at -$1.3 billion (up 21.78% YoY), while the FY2025 annual figure was -$945.4 million, up 74.92% from the prior year.
• Cash from Investing Activities was -$431.9 million for Q1 2026 at Vertex Pharmaceuticals, down from -$288.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $175.6 million in Q4 2022 to a low of -$2.1 billion in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$506.5 million across 5 years, with a median of -$348.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities jumped 231.04% in 2022, then plunged 3495.29% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at $175.6 million in 2022, then plunged by 604.84% to -$886.5 million in 2023, then climbed by 7.29% to -$821.9 million in 2024, then jumped by 64.95% to -$288.1 million in 2025, then sank by 49.91% to -$431.9 million in 2026.
• The last three Cash from Investing Activities figures came in at -$431.9 million (Q1 2026), -$288.1 million (Q4 2025), and -$117.0 million (Q3 2025), per Business Quant data.